[{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Anika Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Two Cells","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"gMSC1","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Two Cells","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Two Cells \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Two Cells \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Ensol BioSciences","sponsor":"Spine BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Ensol BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensol BioSciences \/ Spine BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Ensol BioSciences \/ Spine BioPharma"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spine BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"AGA111","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intervertebral","sponsorNew":"Angitia Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Angitia Biopharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          WRIB
                          Not Confirmed
                          WRIB
                          Not Confirmed

                          Details : AGA111 is a recombinant human bone morphogenic protein 6 (rhBMP6) product in clinical development to promote bone fusion & functional outcomes in patients undergoing spinal fusion procedures.

                          Product Name : AGA111

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 18, 2025

                          Lead Product(s) : AGA111

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          WRIB
                          Not Confirmed
                          WRIB
                          Not Confirmed

                          Details : Spine BioPharma acquired the right to develop and commercialize SB-01, excluding Korea. It is being evaluated for the treatment of pain-related disability, associated with Degenerative Disc Disease.

                          Product Name : SB-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 07, 2024

                          Lead Product(s) : SB-01

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Spine BioPharma

                          Deal Size : $155.0 million

                          Deal Type : Agreement

                          blank

                          03

                          WRIB
                          Not Confirmed
                          WRIB
                          Not Confirmed

                          Details : SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. It is being developed for chronic low back pain in degenerative disc disease.

                          Product Name : SB-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 24, 2024

                          Lead Product(s) : SB-01

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          WRIB
                          Not Confirmed
                          WRIB
                          Not Confirmed

                          Details : Hyalofast is a highly differentiated, single-stage, bone preserving, hyaluronic acid matrix, which is intended to support the entrapment of mesenchymal stem cells obtained from autologous bone marrow aspirate concentrate for the repair of chondral and os...

                          Product Name : Hyalofast

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 30, 2023

                          Lead Product(s) : Hyaluronic Acid

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          WRIB
                          Not Confirmed
                          WRIB
                          Not Confirmed

                          Details : Upon termination of the Agreement, all domestic and foreign rights with respect to guaranteed Mesenchymal Stem Cell 1 (gMSC®1), a regenerative cellular medicine for chondrogenesis in the knee, granted to Chugai from TWOCELLS will be returned to TWOCELLS...

                          Product Name : gMSC1

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 13, 2023

                          Lead Product(s) : gMSC1

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Chugai Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank